BioSpace News Archive

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 15,625,000 shares of its common stock at a public offering price of $0.80 per share

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month and six-month periods ended June 30, 2020.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2020 earnings call and webcast, reporting financial results for the quarter ended June 30, 2020

Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for ciltacabtagene autoleucel (cilta-cel; LCAR-B38M CAR-T cells),

Acutus Medical, Inc. (“Acutus”) (NASDAQ: AFIB) today announced the pricing of its initial public offering of 8,823,529 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by Acutus.

Blue Cross Blue Shield of Massachusetts announced that it will return $101 million in premium refunds and anticipated rebates to its customers and members as a result of lower than anticipated health care costs during the COVID-19 public health emergency.

Rite Aid has named Paul Gilbert as its General Counsel and Corporate Secretary. Since joining Rite Aid on an interim basis earlier this year, Gilbert has played a key role in the company’s efforts to evolve into a destination for whole being health.

Research to focus on potential biomarkers of disease progression, immune and treatment response in the setting of Non-Muscle Invasive Bladder Cancer

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 for the treatment of COVID-19.

WishBone Medical Inc. announced its 5th and 6th strategic acquisition in the past 18 months by acquiring substantially all assets of Back 2 Basics Direct and Orbbö Surgical, two privately-held medical device companies focused on research, development and commercialization of sterile packaged implants and surgical instruments for spinal fusion.